This company has been acquired
Reata Pharmaceuticals Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Reata Pharmaceuticals.
Key information
62.0%
Earnings growth rate
61.0%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 48.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 26 Sep 2023 |
Recent future growth updates
Recent updates
Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
May 10
FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug
Oct 13Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?
Oct 12Reata Pharmaceuticals Q2 2022 Earnings Preview
Aug 05We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth
Jun 22Reata Pharmaceuticals: Once Beaten, Twice Shy
Mar 28Reata's Advisory Committee Hiccup Ruins Its Future Prospects
Dec 31Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
Dec 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 704 | 201 | 116 | N/A | 6 |
| 12/31/2024 | 379 | -149 | -67 | N/A | 8 |
| 12/31/2023 | 89 | -99 | -265 | N/A | 5 |
| 6/30/2023 | 23 | -88 | -249 | -248 | N/A |
| 3/31/2023 | 1 | -354 | -231 | -228 | N/A |
| 12/31/2022 | 2 | -312 | -208 | -204 | N/A |
| 9/30/2022 | 3 | -312 | -280 | -277 | N/A |
| 6/30/2022 | 10 | -305 | -276 | -272 | N/A |
| 3/31/2022 | 11 | -304 | -250 | -249 | N/A |
| 12/31/2021 | 11 | -297 | -237 | -236 | N/A |
| 9/30/2021 | 14 | -278 | -159 | -158 | N/A |
| 6/30/2021 | 8 | -271 | -157 | -156 | N/A |
| 3/31/2021 | 9 | -266 | -327 | -326 | N/A |
| 12/31/2020 | 9 | -248 | -323 | -322 | N/A |
| 9/30/2020 | 8 | -369 | -427 | -427 | N/A |
| 6/30/2020 | 15 | -343 | -428 | -427 | N/A |
| 3/31/2020 | 20 | -310 | -265 | -264 | N/A |
| 12/31/2019 | 27 | -290 | -254 | -251 | N/A |
| 9/30/2019 | 32 | -129 | -142 | -139 | N/A |
| 6/30/2019 | 30 | -120 | -98 | -96 | N/A |
| 3/31/2019 | 29 | -114 | -90 | -88 | N/A |
| 12/31/2018 | 54 | -81 | -84 | -84 | N/A |
| 9/30/2018 | 55 | -72 | -72 | -71 | N/A |
| 6/30/2018 | 62 | -53 | -94 | -93 | N/A |
| 3/31/2018 | 67 | -36 | -86 | -85 | N/A |
| 12/31/2017 | 48 | -48 | -84 | -83 | N/A |
| 9/30/2017 | 50 | -35 | -70 | -70 | N/A |
| 6/30/2017 | 50 | -24 | -47 | -47 | N/A |
| 3/31/2017 | 50 | -13 | N/A | -42 | N/A |
| 12/31/2016 | 50 | -6 | N/A | -19 | N/A |
| 9/30/2016 | 50 | -4 | N/A | -21 | N/A |
| 6/30/2016 | 50 | -2 | N/A | -35 | N/A |
| 3/31/2016 | 50 | -3 | N/A | -35 | N/A |
| 12/31/2015 | 50 | -1 | N/A | -45 | N/A |
| 9/30/2015 | 50 | 0 | N/A | -42 | N/A |
| 6/30/2015 | 51 | 0 | N/A | -42 | N/A |
| 3/31/2015 | 51 | 2 | N/A | -63 | N/A |
| 12/31/2014 | 51 | 1 | N/A | -89 | N/A |
| 12/31/2013 | 51 | -36 | N/A | -69 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RETA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: RETA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RETA is expected to become profitable in the next 3 years.
Revenue vs Market: RETA's revenue (48.1% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: RETA's revenue (48.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RETA's Return on Equity is forecast to be high in 3 years time